5 August 2019 in CHILD`S HEALTH
Background. Acute obstructive bronchitis (AOB) ranks second among the respiratory diseases in children. In recent years, the results of clinical studies demonstrate a correlation between the low level of vitamin D (VD) and the risk of recurrent respiratory infections in adults and children. At the same time, the impact of VD insufficiency/deficiency and timely compensation of these changes on the frequency and severity of broncho-obstructive syndrome (BOS) in young children remains poorly understood. Thus, the purpose of the research was to study the features of VD level in young children with recurrent BOS and the efficacy of vitamin D3 supplementation on incidence and severity of the disease. Materials and methods. We examined 120 children with acute obstructive bronchitis. Group I included 60 patients with episodic BOS (up to 3 episodes per year), group II consisted of 60 children with recurrent BOS (3 or more episodes per year). The control group represented 30 healthy children of the corresponding age. We evaluated the severity of BOS and determined the serum level of 25-hydroxyvitamin D (25(OH)D) using an electrochemiluminescence method. Subsequently, the group of children with recurrent BOS was divided into two subgroups: IIa subgroup included 30 children who received vitamin D3 1000 IU daily throughout the year, IIb included 30 patients who were not supplemented with VD. The effectiveness of vitamin D3 supplementation was determined by the changes in the blood level of 25(OH)D, frequency and severity of BOS episodes. We used non-parametric methods for statistical analysis of data. For all types of analysis, the critical value of the significance level (p) was taken to be < 0.05. Results. The analysis of the clinical features of BOS episode showed that in the group of children with recurrent BOS compared to patients with episodic BOS the disease was characterized by a more severe course (23.3 % vs. 10.0 %, respectively; p = 0.034). We found that the mean VD level in children with recurrent BOS was 13.68 (7.96; 19.51) ng/ml and in children with episodic BOS 33.0 (28.19, 41.97) ng/ml (p < 0.001). The VD supplementation in the group with recurrent BOS was significantly lower than in children who were ill episodically (5 % vs. 60 %; p < 0.001). We showed that the risk of severe episode (OR = 3.06; 95% CI: 1.19–7.84; p = 0.019) and recurrent BOS (OR = 4.35; 95% CI: 2.75–6.86; p < 0.001) is higher in case of 25(OH)D level in serum less than 20 ng/ml. According to our data, VD supplementation in children for one year improves VD level (25.11 (12.14, 42.47) ng/ml vs. 14.48 (10.58, 23.47) ng/ml; p = 0.012) and reduces frequency of BOS episodes (1.0 (0.0; 2.0) in IIa subgroup vs. 2.0 (1.0; 3.0) in IIb subgroup; p < 0.001). On the background of vitamin D3 intake the severe course of BOS was not noticed, unlike the patients who did not receive it (0 % vs. 20 %, respectively; p = 0.031). Conclusions. VD deficiency occurs in 75 % of children with recurrent BOS. Moreover, the serum level of 25(OH)D below 20 ng/ml is associated with an increased risk of recurrent and severe episodes of BOS. Thus, supplementation with vitamin D3 1000 IU per day helps to increase the content of 25(OH)D in serum, to reduce the frequency and severity of BOS.
29 May 2023 in CHILD`S HEALTH
Background. Atypical hemolytic uremic syndrome (aHUS) is an extremely rare but life-threatening disorder in children since it may cause acute kidney injury. Patients with aHUS are at risk of recurrence. Hence, in this paper, we present a case of a 9-year-old boy with aHUS relapse. The child was admitted to the emergency department on the fifth day of illness with main complaints of facial puffiness and decreased urine output. Based on the medical history, the patient developed the second episode of aHUS after 6 years of complete recovery from the first episode. There was no preceding diarrheal illness, instead, the clinical manifestation of both aHUS episodes was triggered by a respiratory tract infection. The results of diagnostic studies performed during the first episode of aHUS were as follows: stool tests for Escherichia coli and Shiga toxins were negative; a complement assay showed no abnormalities; ADAMTS13 activity and anti-complement factor H antibodies were normal. The results of the kidney ultrasonography and biopsy were consistent with the diagnosis. Family history was remarkable for aHUS in a younger sibling confirmed by molecular genetic testing, in particular, a pathogenic variant in the CD46/MCP (membrane cofactor protein) gene in the heterozygous state has been identified. Physical examination revealed paleness, facial swelling, moderate hypertension, and oliguria. Laboratory findings demonstrated hemolytic anemia, thrombocytopenia, significant azotemia, a severe reduction in the glomerular filtration rate, a high level of aspartate aminotransferase, insignificant electrolyte imbalance, and proteinuria. Supportive treatment included fluid and electrolyte management, fresh frozen plasma, furosemide, and dexamethasone. The child commenced acute hemodialysis due to severe acute kidney injury. Conclusions. A recurrence of aHUS is characterized by severe renal failure requiring acute hemodialysis. Viral infections are potential triggers of aHUS. A relapsing course of the disease and a family history of aHUS indicate the importance of genetic screening, as familial aHUS should be considered.
29 December 2024 in CHILD`S HEALTH
Systemic autoinflammatory diseases (SAIDs) are considered dysregulation disorders of the innate immune system characterized by systemic sterile inflammation independent of infection and autoreactive antibodies or antigen-specific T cells. Autoinflammation is often mediated by inflammasomes; accordingly, inflammasomopathies and other enhanced interleukin (IL) 1 signaling syndromes represent a major classification group of SAIDs. Inflammasomes differ by the type of intracellular receptor which acts as a scaffold protein for the entire complex. Specifically, pyrin is one of the main intracellular sensor proteins that can initiate the formation of inflammasomes. This scientific review is the second in a series of publications jointly aiming to increase medical professionals’ awareness of SAIDs in children. It focuses on the current scientific understanding of pyrin inflammasomopathies which represent a significant cluster of all inflammasomopathies and other enhanced IL-1 signaling syndromes. We performed a focused search over the Web of Science, Scopus, PubMed Central®, Google Scholar databases over the past 10 years using the keywords “autoinflammatory diseases”, “autoinflammation”, “inflammasomopathies”, “pyrin”. The work presents an overview of inflammasomopathies, discusses the immunobiological features of the sensor protein pyrin and pyrin inflammasomes including cellular expression and molecular mechanisms of their activation and signal limitation. The review also presents the clinical and pathogenetic characteristics of the genetically determined pyrin inflammasomopathies and other enhanced IL-1 signaling syndromes: familial Mediterranean fever; pyrin-associated autoinflammation with neutrophilic dermatosis; mevalonate kinase deficiency; PSTPIP1-associated inflammatory diseases; periodic fever, immunodeficiency and thrombocytopenia syndrome; neonatal-onset cytopenia with dyshematopoiesis, autoinflammation, rash, and hemophagocytic lymphohistiocytosis; deficiency of IL-1 receptor antagonist; deficiency of IL-36 receptor antagonist; loss of IL-1 receptor to IL-1 receptor antagonist syndrome.